Immunomodulatory Effects of Hemagglutinin- (HA-) Modified A20 B-Cell Lymphoma Expanded as a Brain Tumor on Adoptively Transferred HA-Specific CD4+ T Cells
Figure 8
HA-specific activation stimulates migration of CD4+ T cells into the brain of A20HA brain tumor-bearing mice. (a) Percent (left bars) and CD44 intensity (right bars) of transgenic CD4+Thy1.1+ T cells and nontransgenic CD4+Thy1.1− T cells from brains of A20HA brain tumor-bearing mice and A20HA tumor-free mice measured by FACS on day 18 after the adoptive transfer and HA vaccination. HA-specific CD4+Thy1.1+ T cells were injected i.v. on day 5 after A20HA i.c. inoculation, and virus HA-Vac was delivered i.p. at the same day. Brain pools of three mice in each group were analyzed by FACS 18 days later. A20HA + T cells + HA-Vac, mice that received A20HA tumor cells, HA-specific CD4+Thy1.1+ T cells, and HA-Vac; A20HA + T cells, mice that received A20HA tumor cells and HA-specific CD4+Thy1.1+ T cells; T cells + HA-Vac, mice that received HA-specific CD4+Thy1.1+ T cells and HA-Vac; T cells, mice that received only HA-specific CD4+Thy1.1+ T cells. (b) Photomicrographs of eosin and hematoxylin stained coronal sections of the brains on days 2, 9, and 18 after the adoptive transfer showing growth dynamics of A20HA B-cell lymphoma in BALB/c mice that received HA-specific CD4+ T cells and HA-Vac on day 5 after A20HA i.c. inoculation. Magnifications ×1 (upper row; arrows show the tumor areas) and ×40 (lower row, arrows show single lymphocytes in the tumor areas). .
